Quanterix Named a Recipient of the Massachusetts Life Sciences Center’s Tax Incentive Program for Third Year

Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced it has been awarded $225,000 in tax incentives through the Massachusetts Life Sciences Center’s Tax Incentive Program.

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The awards, which will create 1,325 jobs in the Commonwealth in 2016, are intended to promote the growth of companies engaged in life sciences research and development, commercialization and manufacturing. This year, a large number of applicants were vying for limited resources, making it the most competitive to-date.

“Our administration is committed to maintaining Massachusetts’ global leadership in the life sciences industry, while growing jobs and building prosperity across the Commonwealth,” said Governor Charlie Baker. “Through these smart job-creation incentives, as well as investments in workforce development and emerging technologies, we are working collaboratively to create an environment that fosters private-sector investment and job growth.”

“We’re honored to be recognized by such a prestigious organization, and are grateful for their support over the past years,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “The exceptional momentum we’ve experienced over the past few years would not be possible without our incredibly knowledgeable and dedicated team. We look forward to continuing to invest in talent to advance our single molecule detection technology and work towards our goal of transforming today’s sick care to true, preventative healthcare.”

Quanterix has recognized six consecutive quarters of 100 percent growth and, most recently, secured $46 million in its Series D funding round. The company has been recognized with several industry accolades and awards, including two grants from the GE and NFL Head Health Challenge I and named one of Fast Company’s Most Innovative Companies in 2016. The company’s technology has been showcased in close to 60 peer-reviewed science journal publications, showcasing the tremendous value it has across key therapeutic areas, including neurology, oncology, cardiology, inflammation and infectious disease.

To become a part of the growing Quanterix team, please visit: http://quanterix.com/about/careers.

About Quanterix
Quanterix is a developer of groundbreaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com. Investors can access a webcast of Kevin Hrusovsky’s recent JPMorgan presentation at: http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160505006157/en/